Advertisement

Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease

      Agents that inhibit the renin-angiotensin system (RAS), such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 (AT1) receptor blockers, have considerable benefit in hypertension and heart failure.
      • Lonn E.M.
      • Yosuf S.
      • Jha P.
      • Montague T.J.
      • Teo K.K.
      • Benedict C.R.
      • Pitt B.
      Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.
      ,
      • Pfeffer M.A.
      Enhancing cardiac protection after myocardial infarction rationale for newer clinical trials of angiotensin receptor blockers.
      ,
      • Rajagopalan S.
      • Harrison D.G.
      Reversing endothelial dysfunction with angiotensin-converting enzyme inhibitors. A new trend?.
      These compounds decrease hemodynamic stress, increase nitric oxide bioactivity, and reduce pulse pressure.
      • Porsch-Oezcueruemez M.
      • Kunz D.
      • Kloer H.
      • Luley C.
      Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease.
      ,
      • Strawn W.B.
      • Chappell M.C.
      • Dean R.H.
      • Kivlighn S.
      • Ferrario C.M.
      Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia.
      ,
      • Kaplan N.M.
      Maximally reducing cardiovascular risk in the treatment of hypertension.
      Recent long-term clinical studies have indicated that the addition of an ACE inhibitor decreases morbidity and mortality in patients with stable coronary artery disease.
      The Heart Outcomes Prevention Evaluation Study Investigators
      Effects of an angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in high-risk patients.
      ,
      • Lonn E.
      • Yusuf S.
      • Dzavik V.
      • Doris C.
      • Yi Q.
      • Smith S.
      • Moore-Cox A.
      • Bosch J.
      • Riley W.
      • Teo K.
      Effects of ramipril and vitamin E on atherosclerosis the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE).
      Furthermore, we have previously demonstrated that treatment with irbesartan in patients with early atherosclerosis decreases markers of inflammation that may be sensitive to the oxidative state in the vasculature.
      • Navalkar S.
      • Parthasarathy S.
      • Santanam N.
      • Khan B.V.
      Irbesartan, an AT1 receptor antagonist, reduces markers of inflammation in patients with early atherosclerosis.
      ,
      • Khan B.V.
      • Navalkar S.
      • Khan Q.A.
      • Rahman S.T.
      • Parthasarathy S.
      Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease.
      In the present study, we examine the potential mechanisms by which the addition of either quinapril or irbesartan can regulate vascular function in patients already on a regimen of aspirin and atorvastatin therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lonn E.M.
        • Yosuf S.
        • Jha P.
        • Montague T.J.
        • Teo K.K.
        • Benedict C.R.
        • Pitt B.
        Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.
        Circulation. 1994; 90: 2056-2069
        • Pfeffer M.A.
        Enhancing cardiac protection after myocardial infarction.
        Am Heart J. 2000; 139: S23-28
        • Rajagopalan S.
        • Harrison D.G.
        Reversing endothelial dysfunction with angiotensin-converting enzyme inhibitors. A new trend?.
        Circulation. 1996; 94: 240-243
        • Porsch-Oezcueruemez M.
        • Kunz D.
        • Kloer H.
        • Luley C.
        Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease.
        J Am Coll Cardiol. 1999; 34: 1995-2001
        • Strawn W.B.
        • Chappell M.C.
        • Dean R.H.
        • Kivlighn S.
        • Ferrario C.M.
        Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia.
        Circulation. 2000; 101: 1586-1593
        • Kaplan N.M.
        Maximally reducing cardiovascular risk in the treatment of hypertension.
        Ann Intern Med. 1988; 109: 36-40
        • The Heart Outcomes Prevention Evaluation Study Investigators
        Effects of an angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in high-risk patients.
        N Engl J Med. 2000; 342: 145-153
        • Lonn E.
        • Yusuf S.
        • Dzavik V.
        • Doris C.
        • Yi Q.
        • Smith S.
        • Moore-Cox A.
        • Bosch J.
        • Riley W.
        • Teo K.
        Effects of ramipril and vitamin E on atherosclerosis.
        Circulation. 2001; 103: 919-925
        • Navalkar S.
        • Parthasarathy S.
        • Santanam N.
        • Khan B.V.
        Irbesartan, an AT1 receptor antagonist, reduces markers of inflammation in patients with early atherosclerosis.
        J Am Coll Cardiol. 2001; 37: 440-444
        • Khan B.V.
        • Navalkar S.
        • Khan Q.A.
        • Rahman S.T.
        • Parthasarathy S.
        Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease.
        J Am Coll Cardiol. 2001; 38: 1662-1667